Thymosin Alpha-1: How It Returned to Category 1
FDA Peptide Regulation
35+ countries
Thymosin alpha-1 (thymalfasin/Zadaxin) is approved as a prescription drug in more than 35 countries for hepatitis B and immune enhancement, though it was never FDA-approved in the United States.
Dominari et al., Expert Opinion on Biological Therapy, 2020
Dominari et al., Expert Opinion on Biological Therapy, 2020
View as imageThymosin alpha-1 has one of the stranger regulatory histories in peptide medicine. It is approved in more than 35 countries as a prescription drug for hepatitis B and immune modulation.[1] It has decades of clinical trial data spanning thousands of patients.[2] Yet in the United States, it was never FDA-approved and was instead available through compounding pharmacies until the FDA placed it on the Category 2 restricted list in 2023. In February 2026, that restriction was reversed. Thymosin alpha-1 was moved back to Category 1, restoring compounding pharmacy access under physician prescription.
Key Takeaways
- Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue by Allan Goldstein in the 1970s, with the synthetic form (thymalfasin/Zadaxin) approved in 35+ countries (Dominari et al., Expert Opinion on Biological Therapy, 2020)
- In a randomized controlled trial of 98 chronic hepatitis B patients, 26 weeks of thymosin alpha-1 produced a 40.6% complete virological response vs. 9.4% in untreated controls (Chien et al., Hepatology, 1998)
- A 2024 comprehensive review of human clinical trials found thymosin alpha-1 well-tolerated across hepatitis B/C, sepsis, cancer immunotherapy, and vaccine enhancement studies (Dinetz et al., International Immunopharmacology, 2024)
- Thymosin alpha-1 activates dendritic cells through Toll-like receptor 9 and the MyD88/IRF7 signaling pathway, triggering both innate and adaptive immune responses (Bozza et al., Journal of Immunology, 2007)
- The FDA placed thymosin alpha-1 on Category 2 in 2023, effectively halting compounding; it was removed from Category 2 in September 2024 and restored to Category 1 in February 2026
- In COVID-19 patients, thymosin alpha-1 treatment was associated with reduced mortality and restored T-cell counts, though most evidence comes from observational studies (Bai et al., Journal of Medical Virology, 2023)
What thymosin alpha-1 is and where it comes from
Thymosin alpha-1 (Ta1) is a 28-amino-acid peptide first isolated from calf thymus tissue by Allan Goldstein's laboratory at George Washington University in the 1970s. It is an N-terminally acetylated, acidic peptide with a molecular weight of approximately 3,108 daltons. The thymus gland produces it naturally as part of the immune maturation process that converts bone marrow precursors into functional T-cells.[3]
The synthetic version, thymalfasin, is manufactured through solid-phase peptide synthesis and sold under the brand name Zadaxin. SciClone Pharmaceuticals developed it and brought it to market in multiple countries.[1] Zadaxin is currently approved in more than 35 nations for chronic hepatitis B treatment and as an immune system enhancer. China, Italy, India, and several Southeast Asian countries represent the largest markets.
In the United States, SciClone submitted a New Drug Application, but the FDA did not grant approval. The clinical trials, while showing efficacy, did not meet the FDA's threshold for the specific indication pursued. This left American patients without access to an FDA-approved version, though compounding pharmacies could legally prepare it under section 503A of the Federal Food, Drug, and Cosmetic Act.[2]
How thymosin alpha-1 modulates the immune system
Ta1's mechanism of action centers on dendritic cell activation through Toll-like receptors (TLRs). Bozza and colleagues demonstrated in 2007 that Ta1 activates the TLR9/MyD88/IRF7 signaling cascade, triggering type I interferon production and antiviral cytokine responses. This placed Ta1's mechanism squarely in the innate immune activation pathway, explaining its broad-spectrum effects across viral, bacterial, and fungal infections.[4]
The downstream effects branch in multiple directions. Ta1 stimulates differentiation of CD34+ stem cell precursors into CD4+ and CD8+ T-cells. It activates natural killer cells. It shifts the Th1/Th2 cytokine balance toward Th1, favoring cell-mediated immunity over antibody-mediated responses. This Th1 bias is particularly relevant for viral infections and intracellular pathogens, where cell-mediated killing is the primary defense.[1]
Garaci and colleagues documented Ta1's effects on T-cell maturation and tumor immunology, showing that it enhances the activity of cytotoxic T-lymphocytes against tumor cells while simultaneously reducing T-regulatory cell suppression. This dual action makes it useful as an adjunct to cancer immunotherapy, where the immune system needs both activation and release from immunosuppressive brakes.[5]
What makes Ta1 unusual among immune-modulating peptides is its apparent inability to cause immune overstimulation. The 2024 comprehensive review by Dinetz and colleagues found no reports of autoimmune flares, cytokine storms, or immune-related adverse events across all reviewed human clinical trials. The peptide appears to restore immune function toward normal rather than pushing it beyond baseline.[2]
Clinical evidence: hepatitis, sepsis, cancer, and COVID-19
Hepatitis B
The strongest clinical data comes from chronic hepatitis B trials. In a randomized controlled trial of 98 patients, 26 weeks of Ta1 therapy produced a complete virological response (clearance of both HBV DNA and HBeAg) in 40.6% of treated patients versus 9.4% in untreated controls. A 52-week course produced a 26.5% response rate, suggesting that the shorter regimen was actually more effective.[6]
A phase III multicenter trial was less definitive: 25% of Ta1 patients versus 13% on placebo achieved sustained HBV DNA loss with negative HBeAg (P less than 0.11). The result did not reach conventional statistical significance. This inconsistency between trials was part of the reason the FDA did not approve the hepatitis B indication.[2]
Chen and colleagues reported in 2022 that Ta1 reduced 48-week mortality from 42.4% to 22.8% in patients with hepatitis B-related acute-on-chronic liver failure, a severe and often fatal condition. The hazard ratio for death was 0.50 (95% CI 0.29-0.85, P = 0.011).[7]
Sepsis and critical care
Camerini's 2015 historical review documented Ta1's use in sepsis and immunocompromised states. In patients with severe sepsis, Ta1 treatment was associated with improved HLA-DR expression on monocytes (a marker of immune competence), reduced secondary infections, and improved survival in some trials. The peptide appeared most effective in patients with demonstrable immune suppression at baseline.[8]
Cancer immunotherapy adjunct
Ta1 has been studied as an adjunct to chemotherapy and immunotherapy in melanoma, hepatocellular carcinoma, and non-small cell lung cancer. Garaci documented in 2012 that Ta1 enhanced dendritic cell cross-presentation of tumor antigens and augmented the cytotoxic T-lymphocyte response against tumor cells.[5] The evidence base here is weaker than for hepatitis, consisting primarily of phase I/II trials and case series rather than large randomized controlled trials.
COVID-19
During the pandemic, Ta1 attracted attention for post-viral immune recovery. Bai and colleagues published a 2023 single-cell RNA sequencing study of COVID-19 patients treated with Ta1, showing restoration of T-cell counts and modulation of the immune landscape. Treated patients showed increased naive CD8+ T-cells and reduced exhausted T-cell phenotypes.[9]
Bellet's 2023 review assessed the broader evidence for Ta1 in lung infections, including COVID-19, and concluded that while the immunological rationale was strong and observational data were encouraging, randomized controlled trial evidence in COVID-19 specifically remained limited.[10]
The regulatory timeline: from access to restriction to restoration
Pre-2023: compounding access
Before the FDA's Category 2 action, Ta1 was available through licensed 503A compounding pharmacies with a physician's prescription. Physicians in functional medicine, integrative oncology, and infectious disease prescribed it for immune support in patients with chronic viral infections, recurrent infections, and as cancer immunotherapy adjuncts. There was no FDA-approved version, but compounding was legal because Ta1 was considered a bulk drug substance eligible for 503A compounding.[2]
2023: Category 2 placement
In 2023, the FDA placed Ta1 on its Category 2 list as part of a broader action against peptide compounding. Category 2 substances cannot be compounded under 503A until the FDA's Pharmacy Compounding Advisory Committee (PCAC) evaluates them and the FDA makes a final determination. This effectively halted legal compounding of Ta1 in the United States. The Category 2 classification was controversial because it grouped Ta1 with peptides that had far less clinical evidence.
September 2024: removal from Category 2
In September 2024, the FDA announced that Ta1 was being removed from Category 2 based on the nominators' withdrawal of the substance's nomination. The removal was effective September 27, 2024. The FDA further stated that Ta1 and other peptide bulk drug substances would be reviewed for potential inclusion in the 503A Bulks Regulation at PCAC meetings scheduled for October and December 2024.
December 2024: PCAC review
On December 4, 2024, the PCAC discussed thymosin alpha-1 acetate and thymosin alpha-1 free base as nominated bulk drug substances for 503A compounding. The committee reviewed the clinical evidence, safety data, and compounding considerations.
February 2026: Category 1 restoration
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the Category 2 restricted list would be moved back to Category 1. Ta1 was among them. This restored the legal pathway for licensed compounding pharmacies to prepare Ta1 with a valid physician's prescription.
The announcement did not constitute FDA approval. It simply returned Ta1 to the regulatory status it held before 2023. Reclassification is not the same as FDA approval: compounded Ta1 does not carry an FDA-approved label, is not covered by insurance as an approved drug, and is not manufactured under the same GMP requirements as commercially approved pharmaceuticals.
Why thymosin alpha-1 was a strong reclassification candidate
Of all the peptides placed on Category 2, Ta1 had arguably the strongest case for restoration. Several factors distinguished it from peptides like BPC-157, which remain in a more complicated regulatory position:
Extensive human clinical trial data. Dinetz and colleagues catalogued human trials spanning hepatitis B/C, sepsis, cancer immunotherapy, vaccine enhancement, and HIV immune reconstitution. Most other Category 2 peptides had primarily animal data.[2]
Approval in 35+ countries. Regulatory agencies in China, Italy, India, and elsewhere had independently reviewed the evidence and granted marketing authorization. This international consensus was absent for most other restricted peptides.[1]
Clean safety profile. Across all reviewed clinical trials, serious adverse events attributable to Ta1 were rare. The most common side effects were mild injection site reactions. No immune overstimulation events were documented.[2]
Well-characterized mechanism. Unlike some peptides whose mechanisms remain poorly understood, Ta1's action through TLR9 signaling and dendritic cell activation has been dissected at the molecular level across multiple independent laboratories.[4]
Garaci's 2024 review framed Ta1 as a case study in phenotypic drug discovery, arguing that the peptide's broad immunomodulatory effects were identified through clinical observation before the molecular mechanisms were fully understood. This pattern is common in peptide pharmacology, where in vivo effects often precede mechanistic explanation.[6]
Evidence gaps that persist
Ta1's reclassification restores access, but it does not resolve open scientific questions.
The hepatitis B data is inconsistent. The phase III multicenter trial did not reach statistical significance. Differences in patient populations, HBV genotypes, and treatment durations across trials make it difficult to determine the true effect size. The strongest signal comes from the most severe patients (acute-on-chronic liver failure), where the mortality reduction was dramatic but the sample size was small.[7]
Cancer data consists primarily of small trials and case series. Large phase III randomized controlled trials of Ta1 as a cancer immunotherapy adjunct have not been conducted. The biological rationale is solid, but the evidence grade remains low.
COVID-19 evidence is almost entirely observational. The single-cell RNA sequencing data from Bai and colleagues is mechanistically informative, but the clinical outcomes data comes from non-randomized studies with significant confounding.[9]
The lack of an FDA-approved version means there is no commercially standardized product in the United States. Compounded preparations vary in purity and potency depending on the pharmacy and the source of bulk raw material. This variability is a real limitation that reclassification does not address.
The Bottom Line
Thymosin alpha-1 has decades of clinical evidence across hepatitis, sepsis, cancer, and viral infections, with approval in 35+ countries. The FDA's 2023 Category 2 placement halted U.S. compounding access despite this evidence base. Its return to Category 1 in February 2026 restored the compounding pathway but did not constitute FDA approval. The clinical data, while extensive, remains inconsistent for some indications, and compounded preparations lack the standardization of commercially manufactured drugs.